James Shin
Stock Analyst at Deutsche Bank
(3.04)
# 2,506
Out of 4,547 analysts
83
Total ratings
54.1%
Success rate
5.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Shin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Reiterated: Buy | $1,285 | $1,175.41 | +9.32% | 20 | May 7, 2026 | |
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $40 | $19.10 | +109.42% | 1 | Apr 24, 2026 | |
| STRO Sutro Biopharma | Reiterated: Buy | $51 → $55 | $23.00 | +139.13% | 4 | Mar 25, 2026 | |
| LEGN Legend Biotech | Reiterated: Buy | $60 | $23.54 | +154.89% | 3 | Mar 9, 2026 | |
| MRK Merck & Co. | Upgraded: Buy | $111 → $150 | $126.26 | +18.80% | 9 | Feb 13, 2026 | |
| ABBV AbbVie | Maintained: Hold | $180 → $204 | $256.10 | -20.34% | 7 | Sep 15, 2025 | |
| GILD Gilead Sciences | Maintained: Buy | $120 → $135 | $130.28 | +3.62% | 5 | Aug 11, 2025 | |
| IMTX Immatics | Initiated Coverage: Buy | $10 | $9.41 | n/a | 1 | May 28, 2025 | |
| IMCR Immunocore Holdings | Initiated Coverage: Buy | $65 | $34.48 | n/a | 1 | May 27, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintained: Hold | $45 → $53 | $60.93 | n/a | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $305 | $366.24 | n/a | 5 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $60 → $61 | $117.39 | n/a | 5 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €27.00 | €15.26 | n/a | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.47 | n/a | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $880 → $870 | $675.19 | n/a | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 → $45 | $2.09 | n/a | 2 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $24.05 | n/a | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $11 | $5.48 | n/a | 1 | Mar 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 | $0.00001 | n/a | 1 | Dec 12, 2022 |
Eli Lilly and Company
May 7, 2026
Reiterated: Buy
Price Target: $1,285
Current: $1,175.41
Upside: +9.32%
Ascentage Pharma Group International
Apr 24, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $19.10
Upside: +109.42%
Sutro Biopharma
Mar 25, 2026
Reiterated: Buy
Price Target: $51 → $55
Current: $23.00
Upside: +139.13%
Legend Biotech
Mar 9, 2026
Reiterated: Buy
Price Target: $60
Current: $23.54
Upside: +154.89%
Merck & Co.
Feb 13, 2026
Upgraded: Buy
Price Target: $111 → $150
Current: $126.26
Upside: +18.80%
AbbVie
Sep 15, 2025
Maintained: Hold
Price Target: $180 → $204
Current: $256.10
Upside: -20.34%
Gilead Sciences
Aug 11, 2025
Maintained: Buy
Price Target: $120 → $135
Current: $130.28
Upside: +3.62%
Immatics
May 28, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $9.41
Upside: n/a
Immunocore Holdings
May 27, 2025
Initiated Coverage: Buy
Price Target: $65
Current: $34.48
Upside: n/a
Bristol-Myers Squibb Company
Feb 10, 2025
Maintained: Hold
Price Target: $45 → $53
Current: $60.93
Upside: n/a
Nov 26, 2024
Maintained: Hold
Price Target: $305
Current: $366.24
Upside: n/a
Sep 19, 2024
Maintained: Hold
Price Target: $60 → $61
Current: $117.39
Upside: n/a
Aug 12, 2024
Maintained: Buy
Price Target: €27.00
Current: €15.26
Upside: n/a
Aug 9, 2024
Reiterated: Buy
Price Target: $10
Current: $1.47
Upside: n/a
Aug 1, 2024
Rated: Hold
Price Target: $880 → $870
Current: $675.19
Upside: n/a
Mar 8, 2023
Maintained: Buy
Price Target: $3 → $45
Current: $2.09
Upside: n/a
Mar 8, 2023
Maintained: Buy
Price Target: $12
Current: $24.05
Upside: n/a
Mar 5, 2023
Maintained: Hold
Price Target: $11
Current: $5.48
Upside: n/a
Dec 12, 2022
Maintained: Buy
Price Target: $7
Current: $0.00001
Upside: n/a